Anibal Perez-Lloret

Title: Anibal Perez-Lloret: Innovator in Osteoporosis Treatment

Introduction

Anibal Perez-Lloret is a notable inventor based in Buenos Aires, Argentina. He has made significant contributions to the field of medicine, particularly in the treatment of osteogenesis imperfecta and the modulation of osteoblasts. With a total of two patents to his name, his work has the potential to improve the quality of life for many individuals suffering from bone-related conditions.

Latest Patents

One of his latest patents focuses on the use of bisphosphonates for the treatment of osteogenesis imperfecta. This innovative procedure involves a two-stage administration of bisphosphonate preparation. In the first stage, a sufficient quantity is administered to achieve a normal range of volumetric mineral density in the cortical tissue. The second stage allows for a controlled interruption of the bisphosphonate to enable the development of sectional momentum of inertia. This method enhances fracture resistance by carefully managing the periods of administration based on precise osteologic variables.

Another significant patent involves the uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid. This invention relates to its novel applications in the manufacture of a medicament aimed at selectively modulating osteoblasts. These advancements highlight his commitment to improving therapeutic options in bone health.

Career Highlights

Throughout his career, Anibal has worked with various companies, including Gador S.A. His experience in the pharmaceutical industry has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Anibal has collaborated with notable professionals in his field, including Emilio J. A. Roldan and Guillermo Vazquez. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his inventions.

Conclusion

Anibal Perez-Lloret is a distinguished inventor whose work in the field of osteogenesis imperfecta and osteoblast modulation showcases his dedication to medical innovation. His patents reflect a deep understanding of bone health and a commitment to improving patient outcomes.